From L to R: Milestones Campaign Chair Joe O’Donnell, CF Foundation Board Chair Cam McLoud and President and CEO of the CF Foundation Robert J. Beall, Ph.D., gathered at a recent reception for major donors at the Canadian Embassy in Washington, D.C.
In October 2005, the Cystic Fibrosis Foundation formally kicked off the Milestones to a Cure campaign to raise essential funds for the development of potential new CF therapies. Since then, the national major giving campaign has been off to a great start. Campaign steering committees are currently being established at each of the CF Foundation chapters, and many have already drawn tremendous local support. Under the leadership of John Burch, Jr., the Tennessee Chapter has gained strong backing and is poised to reach its $1 million goal by the end of 2006. In Chicago, Rich Gray, Chris Stevens and others are leading the major gifts effort among the Greater Illinois Chapter’s region and are close to achieving their own $1 million goal. Overall, the Milestones campaign has received approximately $90 million in commitments to date and is on track to achieve its $175 million goal by 2010.
“I am enormously pleased that so many great friends have given to the Milestones campaign, and I am confident that with the increased efforts of campaign committees and volunteers across the nation, we will continue to expand our support for essential CF therapeutics development,” Joe O’Donnell, Milestones chair, noted recently.
Thanks to this critical support, the CF Foundation continues to build relationships with biopharmaceutical companies like Vertex and CombinatoRx that can apply cutting-edge technology to the CF research effort. To ensure that the Foundation can pursue all new avenues of research and that all viable drug candidates move swiftly from laboratory to pharmacy, more support is needed. “We need the vital support of the Milestones to a Cure campaign,” President and CEO of the CF Foundation Robert J. Beall, Ph.D., recently commented, “to continue to accelerate advances that will lead us to better therapies and a cure for this disease.”